# US 2026/0098066 A1 · Method of Treatment Using a Pharmaceutical Composition Comprising a p80 Protein

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0098066 A1
- Document ID: US20260098066A1
- Status: Published application
- Kind: A1
- Application number: 19/352,455
- Filed: 2025-10-07
- Published: 2026-04-09
- Earliest claimed: 2020-09-17
- Assignees: Prime Bio, Inc.
- Applicants: Prime Bio, Inc.
- Inventors: Bal Ram Singh; Raj Kumar
- Web page: https://patentgrep.com/patent/US20260098066A1

## CPC

- C07K 14/33: from Clostridium (G)
- A61K 38/4893: {Botulinum neurotoxin (3.4.24.69)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C07K 1/18: Ion-exchange chromatography
- C12N 9/52: derived from bacteria {or Archaea}
- C12Y 304/24069: Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12R 2001/19: Escherichia coli
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES
- C12R: INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Present invention relates to a method of treating a disorder by administering an effective amount of a pharmaceutical composition comprising a therapeutic agent bound to a p80 neurotoxin associated polypeptide (NAP) derived from Clostridium Botulinum Type E (BoNT/E). The p80 is bound to a therapeutic agent, comprising one or more of: drugs, dyes, small molecules, biomolecules, proteins or a combination thereof. P80 enhances the transportation of the therapeutic agent into the bloodstream for increased bioavailability because thep80 is a tight junction modulator to enhance the permeability of the intestinal epithelium so as to facilitate drug delivery.

## Claims

### Claim 1

A method of treatment comprising administrating an effective amount of a non-naturally occurring pharmaceutical composition comprising:
i) an isolated native and/or a recombinant bioenhancer p80 neurotoxin associated polypeptide (NAP) bound to at least one therapeutic agent that is equal to or less than 150 kDa;
ii) wherein the at least one therapeutic agent comprises one or more of: drugs and biomolecules; and
iii) wherein the isolated and/or recombinant p80 NAP is a bioenhancer to the at least one therapeutic agent resulting in the at least one therapeutic agent having a higher bioavailability after being translocated across an intestinal epithelium into a circulating blood as compared to a pharmaceutical composition without the p80 NAP.

### Claim 2 (depends on 1)

The method as claimed in claim 1, wherein method of administration is oral route, sublingual and buccal routes, rectal route, vaginal route, ocular route, optic route or nasal route.

### Claim 3 (depends on 1)

The method of claim 1, wherein the p80 comprises SEQ ID NO: 1.

### Claim 4 (depends on 1)

The method of claim 1, wherein the p80 comprises SEQ ID NO: 2.

### Claim 5 (depends on 1)

The method of claim 1, wherein the bioenhancer p80 NAP is native p80 NAP obtained from a Clostridium botulinum neurotoxin.

### Claim 6 (depends on 1)

The method of claim 1, wherein the bioenhancer p80 NAP is recombinant p80 NAP obtained from recombinant technologies.

### Claim 7 (depends on 1)

The method of claim 1, wherein the bioenhancer p80 NAP is native p80 NAP and obtained from Clostridium toxins.

### Claim 8 (depends on 1)

The method of claim 1, wherein the bioenhancer p80 NAP is native or recombinant p80 NAP, and the pharmaceutical composition further comprises a microsphere encapsulating the native or recombinant p80 protein and the at least one therapeutic agent.

### Claim 9 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition further comprises one or more Clostridium neurotoxin associated polypeptides (NAPS) comprising: p118, p65, p40, and p18.

### Claim 10 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition is in a lyophilized or a gel form.

### Claim 11 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition is stabilized at a pH in between 5.5 and 8.0.

### Claim 12 (depends on 5)

The method of claim 5, wherein the bioenhancer p80 NAP is a recombinant p80 NAP of 80 kDa molecular weight, and obtained from Clostridium botulinum neurotoxin type E (BoNT/E) complex.

### Claim 13 (depends on 1)

The method of claim 1, wherein the therapeutic agent further comprises: dyes, small molecules, surface active agents, chelating agents, salicylates, anti-inflammatory agents, phenothiazines, stabilizers, therapeutic proteins or a combination-thereof.
